NCT02669758: A reported trial by Alkermes, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02669758 |
|---|---|
| Title | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 20, 2016 |
| Completion date | June 29, 2018 |
| Required reporting date | June 29, 2019, midnight |
| Actual reporting date | June 18, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |